J&J's Janssen Gets Canada OK for Stelara in Ulcerative Colitis in Adults
January 27 2020 - 11:58AM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit
on Monday said Health Canada approved the expanded use of Stelara
for adults with moderately to severely active ulcerative
colitis.
The drug maker said the approval is based on a phase 3 study in
which Stelara induced and maintained clinical remission in a
significantly greater proportion of patients with the inflammatory
bowel disease compared with placebo.
Janssen said Stelara is now indicated in Canada for adults with
Crohn's disease, ulcerative colitis, psoriasis and active psoriatic
arthritis, and for adolescents with psoriasis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 27, 2020 11:43 ET (16:43 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2023 to Sep 2024
